Observational influenza vaccine active surveillance study: A Phase IV Prospective Multi-Centre Cohort Study to Evaluate the Reactogenicity of bioCSL’s influenza virus vaccine (CSLCT-SAF-14-05)

First published 22/08/2014

Last updated 25/07/2016

EU PAS number:

EUPAS7301

Study

Finalised

Download as PDF

Documents

Study protocol

Initial protocol

CSLCT-SAF-14-05_PASS Abstract_V1_4-AUG-14

English (111.97 KB - PDF) View document

Study results

RESULT SUMMARY for CSLCT-SAF-14-05 - Final_10Aug15

English (88.73 KB - PDF) View document

Study report

Other information

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Signed checklist for study protocols

CSLCT-SAF-14-05_PASS protocol_4-AUG-14_Annex 2 ENCePP checklist

English (205.96 KB - PDF) View document

Observational influenza vaccine active surveillance study: A Phase IV Prospective Multi-Centre Cohort Study to Evaluate the Reactogenicity of bioCSL’s influenza virus vaccine (CSLCT-SAF-14-05)

Secondary tabs

Share this page